Patient with photoaging skin non-crosslinked hyaluronic acid, facial rejuvenation
Conditions
Interventions
Patients were injected with MPT non-crosslinked hyaluronic acid for three sessions at one-month intervals. They were then instructed to follow up at 1, 2, 3, 6, and 9 months after the final treatment.
Experimental Device
MPT non-crosslinked hyaluronic acid
Sponsors
Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
Eligibility
Sex/Gender
All
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Male and female Thai volunteers aged between 20 - 60 years. 2. Individuals with early-stage photoaged skin, as assessed by at least one of the following criteria: 2.1. Uneven skin tone 2.2. Fine wrinkles 2.3. Dry skin 2.4. Skin laxity
Exclusion criteria
Exclusion criteria: 1. Pregnant or breastfeeding women. 2. Volunteers with a history of platelet disorders, coagulation abnormalities, anemia, liver disease, cancer, or autoimmune disorders. 3. Volunteers who smoke or have a history of heavy alcohol consumption. 4. Volunteers with dermatitis, wounds, or skin infections on the face. 5. Volunteers with a history of allergy to local anesthetics. 6. Volunteers who regularly take hormones, contraceptives (oral or injectable), or NSAIDs. 7. Volunteers taking anticoagulants or antiplatelet drugs such as aspirin. 8. Volunteers who have undergone facial tightening procedures (e.g., energy-based devices or thread lifting) within 6 months prior to participation. 9. Volunteers who have received filler injections on the face within 6 months prior to participation. 10. Volunteers who have undergone platelet-rich plasma (PRP) injections on the face within 6 months prior to participation. 11. Volunteers who have received botulinum toxin injections on the face within 6 months prior to participation. 12. Volunteers who have undergone collagen-stimulating laser treatments on the face (e.g., Picosecond laser, Er:YAG laser, Fractora, or E-matrix laser) within 6 months prior to participation. 13. Volunteers with a history of keloid formation. 14. Volunteers diagnosed with psychiatric disorders by a psychiatrist.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Wrinkle depth Baseline, 2nd treatment, 3rd treatment, 1, 2, 3, 6 and 9 months after 3rd treatment Antera,Hydration Baseline, 2nd treatment, 3rd treatment, 1, 2, 3, 6 and 9 months after 3rd treatment Corneometer,Wrinkle index Baseline, 2nd treatment, 3rd treatment, 1, 2, 3, 6 and 9 months after 3rd treatment Antera,Texture Baseline, 2nd treatment, 3rd treatment, 1, 2, 3, 6 and 9 months after 3rd treatment Antera | — |
Secondary
| Measure | Time frame |
|---|---|
| R0 parameter (indicate skin firmness) Baseline, 2nd treatment, 3rd treatment, 1, 2, 3, 6 and 9 months after 3rd treatment Cutometer,R2 parameter (indicate skin elasticity) Baseline, 2nd treatment, 3rd treatment, 1, 2, 3, 6 and 9 months after 3rd treatment Cutometer,Redness Baseline, 2nd treatment, 3rd treatment, 1, 2, 3, 6 and 9 months after 3rd treatment Mexameter,Pigmentation Baseline, 2nd treatment, 3rd treatment, 1, 2, 3, 6 and 9 months after 3rd treatment Mexameter,Sebum level Baseline, 2nd treatment, 3rd treatment, 1, 2, 3, 6 and 9 months after 3rd treatment Sebumeter,ITA value Baseline, 2nd treatment, 3rd treatment, 1, 2, 3, 6 and 9 months after 3rd treatment colorimeter,Volume change Baseline, 2nd treatment, 3rd treatment, 1, 2, 3, 6 and 9 months after 3rd treatment Vectra H2,Safety Baseline, 2nd treatment, 3rd treatment, 1, 2, 3, 6 and 9 months after 3rd treatment Adverse event,Physician improvement scale Baseline, 2nd treatment, 3rd treatment, 1, 2, 3, 6 and 9 months after 3rd treatment percent improvement, Patient Improvement scale Baseline, 2nd treatment, 3rd treatment, 1, 2, 3, 6 and 9 months after 3rd treatment percent improvement,Pain score Baseline, 2nd treatment, 3rd treatment Visual analog scale | — |
Countries
Thailand
Contacts
Public ContactRungsima Wanitphakdeedecha
Faculty of Medicine Siriraj Hospital, Mahidol University
Outcome results
None listed